What to expect from Jazz Pharmaceuticals's (JAZZ) Q3 earnings

What happened

Jazz Pharmaceuticals will report its third-quarter results this Monday after market hours. Last quarter it reported revenues of $1.21 billion, up 15.5% year on year, beating analysts' expectations. This quarter, the market expects revenue to grow 7.4% year on year.

Confirmed

Global impact / market context

Revenue growth of 7.4% would be slower than last quarter's 15.5%, so investors will watch whether demand holds up. Analysts have reconfirmed estimates, suggesting no big surprises are expected. Peer results give a clue on how the sector is performing.

Analyst inference

Eli Lilly reported revenue growth of 38.6% and beat estimates by 7.9%, while Supernus Pharmaceuticals grew 18.1% and topped estimates by 3.9%. These peer results suggest parts of the pharmaceuticals segment are still growing strongly, which may shape expectations for Jazz.

Analyst inference

What to watch

1. Jazz Pharmaceuticals reports results this Monday after market hours, and the market expects revenue to grow 7.4% year on year, in line with the 6.7% increase in the same quarter last year. Confirmed
2. Watch whether Jazz Pharmaceuticals meets the 7.4% revenue growth expectation and whether management comments on demand and costs, since these affect revenue and profit per sale. Proposed
3. Compare Jazz's results with Eli Lilly's 38.6% and Supernus's 18.1% revenue growth to judge if Jazz is gaining or losing share within the pharmaceuticals segment. Analyst inference

Evidence

• stockstory.org